自体细胞因子诱导的杀伤细胞联合XELOX方案治疗晚期胃癌的疗效观察

Autologous cytokine-induced killer cells combined with XELOX regimen in treatment for patients with advanced gastric cancer

摘要:

目的 观察自体细胞因子诱导的杀伤细胞(CIK)联合XELOX方案治疗晚期胃癌的疗效。方法 回顾性分析经病理学确诊的晚期胃癌患者65例。随机分为两组：观察组32例，采用自体CIK细胞联合XELOX方案化疗；对照组33例，单独采用XELOX方案化疗。疗程为2周期，治疗结束后对两组的近期疗效、免疫功能、毒副反应进行评价。结果 观察组客观缓解率（ORR）为46.88%，对照组为39.39%，差异无统计学意义（P > 0.05）；观察组疾病控制率（DCR）为78.13%，对照组为54.55%，差异有统计学意义（P <0.05）。观察组T细胞亚群CD3+、CD4+、CD56升高，CD4+/CD8+比值上升，差异有统计学意义（P <0.05）。观察组骨髓抑制、胃肠反应、神经毒性、手足综合征不良反应发生率低于对照组，差异有统计学意义（P <0.05）。结论 自体CIK细胞联合XELOX方案治疗晚期胃癌可以提高近期疗效，增强患者免疫功能，减轻毒副作用,值得临床推广使用。

Abstract:

【Objective】 To observe the efficacy of autologous cytokine-induced killer (CIK) cells combined with XELOX regimen in the treatment for patients with advanced gastric cancer. 【Methods】 A total of 65 patients with advanced gastric cancer confirmed by pathology were retrospective analyzed. They were randomly divided into two groups with 32 cases in observation group and 33 cases in control group. The observation group was given CIK cells combined with XELOX regimen, while the control group was given XELOX regimen alone. The recent curative effect, immunity and side effects were compared between both groups after two cycles of chemotherapy. 【Results】 The Objective Response Rate (ORR) was 46.88% in the observation group and 39.39% in the control group; the difference between the two groups was not statistically significant (P > 0.05). The Disease Control Rate (DCR) was 78.13% in the observation group and 54.55% in the control group, the difference between both groups was statistically significant (P < 0.05). After treatment CD3+, CD4+, CD56 and the ratio of CD4+/CD8+ were significantly increased in the observation group (P < 0.05). The incidences of side effects in the observation group were obviously lower than those in the control group (P < 0.05). 【Conclusions】 Autologous CIK cells combined with XELOX regimen could increase the curative effectand enhance the immunity of the patients with advanced gastric cancer, meanwhile reduce side effects.